GPC3CD3 Trial

A phase 1/2 study of SAR444200, an anti-GPC3/CD3 bispecific antibody in patients with advanced solid tumors
Status:

Open

Trial Type:
Colon Cancer, Esophageal Cancer, Liver and Bile Duct Cancer

Contact:

Khaldoun Almhanna, MD
kalmhanna@brownhealth.org

©2025 Brown Cancer Trials